



A DECADE SHORT REVIEW ON NANOPARTICLES APPROACHES APPLIED TO THE DELIVERY OF ANTIEPILEPTIC DRUGS

R Devi^{*1}, M Komala², B Jayanthi¹

¹ Department of Pharmacy, FEAT, Annamalai University, Chidambaram – 608002.
Tamilnadu

²School of Pharmaceutical Sciences, Vel's Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117

*Corresponding author E-mail: devivarshni@gmail.com

ARTICLE INFO

ABSTRACT

Key Words

Antiepileptic,
Nanoparticles,
Blood-brain barrier.

Access this article online

Website:

<https://www.jgtps.com/>

Quick Response Code:



Medication access to the brain is seriously restricted by various biological elements, especially the blood-brain boundary, which hinders the capacity of anti epileptic drugs to enter and stay in the brain. To improve the adequacy of drugs, new medication conveyance methodologies are being created; these strategies fall into the three principle methods like drugs Modification, blood-brain barrier adjustment, and direct medication conveyance. As of late, every one of the three techniques have been improved using drug-stacked nanoparticles. This short review provides the type of nano carriers used for the drugs to be delivered in to brain.

INTRODUCTION

The human brain is the most important part of human body as well as midpoint of the whole nervous system. Thus it is protected by 2 major parts name as; physiological along with anatomical barriers BBB “Blood-Brain Barrier” as well as BCSFB “Blood-Cerebrospinal Fluid Barrier” to regulate its homeostasis. BBB is an organized and complex multicellular structure which mainly guards the brain against unnecessary elements as well as invading organisms, therefore it protects against different brain injuries along with diseases. Nevertheless, it impedes the real drug delivery into the human brain, therefore, prevent treatment of many neurological

ailments. Neurological sicknesses (like; Cerebrovascular disease, Brain tumor, Migraine, Epilepsy, Stroke, Several Sclerosis, ADC (AIDS Dementia Complex), Alzheimer’s ailment, Parkinson’s ailment, and Huntington ailment, so on are an essential contributors for global mortality as well as total deaths account in whole world is 12%. Drug delivery is the most difficult part of treating brain illness through the barriers instead of developing a new therapy. It was expected that more than 98% of these drug discovery pipelines may not spend the BBB adequately to achieve concentration of therapeutic drugs. Overcoming the barrier methods could, therefore, result in the profitable therapy of much neurological illness. Although different

traditional methods for example; ICV (Intra-Cerebro-Ventricular) injection, implants, and prodrugs usage, and BBB disruption have accomplished some achievements in conquering the barriers, scientists are continually working hard for enhanced drug delivery system. A primary technique which makes use of BBB limiting in the process of delivery of drug to the brain might involve:

- (a) Lack of paracellular openings
- (b) Absence of pinocytosis
- (c) Essential protein mediated efflux

Hence, essential research is also contributed to developing technologies as well as techniques to avoid BBB for brain drug delivery [1].

For effectively drugs release to the human brain, different strategies are established. They contain chemical changes of prodrugs and drugs, tight junction's temporary disruption, in the brain the local delivery has been done through neurosurgery, as well as mediated delivery of nanoparticles. (Ref 7). The role of the BBB is highly recognizable for establishing the treatments mainly directing neurodegenerative illness. BBB methods are profoundly examined for the pathology: among the key crucial illnesses of the CNS, this evaluation concentrates on the use of nanoparticles primarily based on nanomedicines to neurodegenerative disorder epilepsy. The BBB is realized as the main barrier for treating neurological illness because it hinders the distribution of numerous essential therapeutic as well as analysis materials to the CNS. In order to overcome BBB restricting medication delivery of prospective therapeutic elements, a medication badly sent out to human brain could be packed on the nanocarrier that interacts together with the BMEC at the BBB as well as generates high drug concentration in parenchyma of human brain. Likewise, the surface of the nanocarrier is additionally customized with focusing on ligands for binding the therapeutic target for improved CNS permeability and selectivity. These nanosystems are leading an excellent likely as medication carriers on the human brain, because of several benefits, and therefore are turning into a substitute to the existing medical as well as traditional techniques. Nevertheless,

more optimization of nanosystem, new designs as well as technologies should be made for developing CNS therapeutics having enhanced BBB permeability. Nonetheless, recently the introduction of Nano medicines might give a potent tool for implementing CNS levelled delivery of some essential active compounds.

Role of Barriers [2]:

Blood-Brain Barrier (BBB)

BBB is a specific cell group that provides a vital struggle for delivering a drug to the human brain. It functions as an all-natural gatekeeper for protecting the human from harmful things in the blood stream whereas providing it essential nutrients for the proper functioning. It's a really complicated and hugely structured multicellular framework comprising of constant levels of highly sealed BCEC's (Brain Capillary Endothelial Cells) sheeted through astrocytes end feet as well as pericytes with the basal lamina. Neurons, Microglia along with another various kinds of cells are also essential parts of the neurovascular. The human brain' endothelial cells are extensively distinct from the cells which are contained in other areas of the entire body, primarily because of:

- (a) Existence of continuous intercellular TJ's (Tight Junctions)
- (b) Reduced paracellular diffusion of elements of water soluble (such as hydrophilic molecules),
- (c) higher metabolic activity because of the existence of comparatively significant amount of mitochondria
- (d) A number of active transporters.

TJ among these neighboring BCECs is created through numerous complicated transmembrane protein (such as JAM-1 (Junctional Adhesion Molecule-1), Occludin and Claudins) having cytoplasmic addition protein-rich foods (like Cingulin, ZO (Zonula occludens)). Several elements are exclusively connected to an actin cytoskeleton to make this best intimate cell to cell interconnection. A molecule should be lipophilic/ hydrophobic for crossing BBB passively as well as should possess a molecular weight below 400Da to 500Da. But most of the small molecular medicines don't have these two

requirements and therefore not able to cross the BBB. New possibilities well as avenues have been opened for the perception of cellular and molecular BBB's biology for greater distribution of medication throughout the BBB. Different transport, receptors and enzymes system are realized in the BCECs which limit the particles permeation for instance peptides as well as proteins are moved by Receptor mediated transcytosis.

Blood-Cerebrospinal Fluid Barrier (BCSFB): After BBB, BCSFB "Blood-Cerebrospinal Fluid Barrier" is 2nd main barrier that is administered systemically before enter the human brain. Basically this may create by tightly sealed epithelial choroid plexus cells lining the ventricular system. CSF (Cerebrospinal fluid) is secreted by it that is dispersed throughout the ventricles as well as near the CNS (spinal cord and brain). It performs together with the BBB, to manage the surroundings of the human brain inside. Hence it's apparent the endothelial cells of the human brain blood vessels, as well as the epithelial cells of the choroid plexus, restrict the penetration of high solute particles from the blood circulation straight in to the brain along with CSF.

Strategies for nanoparticles to cross the BBB [3]

- (a) Receptor mediated endocytosis
- (b) Drug transport among BBB through Physical approaches (invasive)
- (c) Drug transport among BBB through CPPs (cell penetrating peptides)
- (d) Bypass BBB via passive targeting
- (e) Bypass BBB via intranasal delivery

Combinational strategies: Epilepsy is generally a major typical global neurological illness that may be counted as a spectrum illness due to its different causes. Its ability also varies in severity as well as its effect varies from person to person and existing conditions.

METHODOLOGY

Search Strategy: The data associated with antimicrobial as well as statin effect were obtained from Pub Med [from September 1987

(first approval) to April 2019]. In PubMed, many nanoparticles along with epilepsy terms were combined and searched. The main objective of present research is to compile the different works related to nanoparticles and epilepsy were coined. In accordance with this, the posts are even more sorted away on the foundation of exclusion as well as inclusion requirements that are pointed out below.

Inclusion and Exclusion Criteria: Inclusion Criteria: research articles generally published from April 2009 to April 2019, associated with Nanoparticles and free full text articles.

Exclusion Criteria: Abstracts

RESULTS

The extracted articles (14) have been selected due to exclusion and inclusion criteria. Several articles included as well as identified for final analysis that has been shown in (Table. 1).

Summary: Summing up, aside from some developments for the design of nanoparticles can effectively cross the BBB, we nevertheless have to raise the precise knowledge of accurate interactions between various features, associated with a nanoparticle system, resulting in a profitable BBB crossing. In order to understand better, interactions will bring about a far more exact as well as prosperous nanoparticle design that might be ready to effectively provide diagnostic and/or therapeutic molecules to the CNS [15]. The treatment, as well as diagnosis of epilepsy, are extremely complicated as well as many patients who are suffering from this particular pathology are rising. Actually, a few reasons are accountable for an outbreak of pathologies like neurotherapies or tumors for neurodegenerative illness. Discovering new drug is not necessary, but also to re-formulate consolidated treatment for reducing unwanted side effects, a rise of patient conformity, particularly throughout persistent therapy, as well as for crossing the BBB, that is a pertinent struggle for CNS treatment. Presently, nose-to-brain delivery is a good approach for overcoming BBB.

Table 1. Nanoparticles approaches applied to the delivery of antiepileptic drugs

Drug	Raw Material	Type of Nano carrier	<i>In Vitro</i> Study	<i>Ex-Vivo/In Vivo</i> Study	Animals	Authors	Year
Iron oxide	SPIONs, anti-IL-1 β -mAb-SPIONs, or AMT-anti-IL-1 β -mAb-SPIONs	Superparamagnetic iron oxide magnetic nanoparticles		Temporal lobe epilepsy	Rats	Yanli Wang et al., [4]	2018
QX-314		Microcapsule		Open-field test for explorative behavior and anxiety	Rats	Olga Kopach et al., [5]	2017
Platinum		Nanoparticles		miRNA hybridisation; fabrication of sandwich assay in microfluidic disc and detection of the miRNA target	Humans	Hazel McArdle et al.,[6]	2017
Diazepam	diazepam loaded PLGA nanoparticles	Polymeric nanoparticles	Dialysis bag method in-vitro drug release			Bohrey et al. [7]	2016
Phenytoin	PHT-loaded ANG-ERHNPs (ANG-PHT-HNPs) and PHT-loaded nonelectroresponsive hydrogel nanoparticles (ANG-PHTHNPs)	Electroresponsive Nanoparticles		Maximal Electroshock-induced Seizures Pentylentetrazole-induced Seizure	Rats	Yi Wang et al., [8]	2016

Iron Oxide	superparamagnetic iron oxide nanoparticles (SPIONs)	Nanoparticles		Acute Temporal Lobe Epilepsy Pilocarpine-Status Epilepticus (SE) Model	Rats	Tingting Fu et al., [9]	2016
Oxcarbazepine coumarin-6		Nanoparticles Cryo-electron microscopy (cryo-EM)	In vitro release studies			antonio lopalco et al., 15 [10]	2015
Lorazepam	PLGA	Nanoparticles	Cell viability on Vero cell line MTT assay		Rats	Sharma D. et al.[11]	2014
Magnesium Oxide		Nanoparticles		Anticonvulsive Effect strychnine-induced convulsion	Albino mice	Leila Jahangiri et al., [12]	2013
carbamazepine	Chitosan	chitosan solid lipid nanoparticles	In-vitro diffusion studies			Rahul Nair et al., [13]	2012
DY-675-g7-Poly(lactic-co-glycolic acid)		Nanoparticles	<i>In vitro</i>		Mice	Kam Leung et al., [14]	2011

The AEDs delivery was discussed and proposed in this chapter. For overcoming several limitations, it was proven with nasal administration, nanomedicine is ready, enhanced and effectively indicated by a number of researchers. Sustained and controlled release nanosystems are a legitimate strategy to answer the need.

REFERENCES

1. Lockman P.R, Koziara J. M, Mumper R. J, & Allen D. D. Nanoparticle Surface Charges Alter Blood – Brain Barrier Integrity and Permeability. *J Drug Target.* 2004;12: 635–641. <https://doi.org/10.1080/10611860400015936>
2. Sarkar A, Fatima I, Mohammad Q, Jamal S, Sayeed U, Khan M. K. A, Siddiqui M. H. Nanoparticles as a Carrier System for Drug Delivery across Blood Brain Barrier. *Curr Drug Metab.* 2017; 129–137. <https://doi.org/10.2174/13892002186661701131251>
3. Zhang T, Li W, Meng G, Wang P, & Liao W. Strategies for transporting nanoparticles across the blood–brain barrier. *Biomaterials Science.* 2015; 4(2):219-29. <https://doi.org/10.1039/c5bm00383k>
4. Wang Y, Ying X, Chen L, Liu Y, Wang Y, Liang J, Chen Z. Electroresponsive Nanoparticles Improve Antiseizure Effect of Phenytoin in Generalized Tonic-Clonic Seizures. *Neurotherapeutics.* 2016; 13(3): 603–613. <https://doi.org/10.1007/s13311-016-0431-9>
5. Kopach O, Zheng K, Dong L, Sapelkin A, Voitenko N, & Sukhorukov G. B. Nano-engineered microcapsules boost the treatment of persistent pain. *Drug Delivery.* 2018;25(1):435-447. <https://doi.org/10.1080/10717544.2018.1431981>
6. Mcardle H, Jimenez-mateos E. M, Raouf R, Carthy E, Boyle D, Delanty N, Henshall D. C. “TORNADO ” – Theranostic One- Step RNA Detector ; microfluidic disc for the direct detection of microRNA-134 in plasma and cerebrospinal fluid. *Sci Rep.*2017;7, 1750 . <https://doi.org/10.1038/s41598-017-01947-2>
7. Bohrey S, Chourasiya V, & Pandey A. Polymeric nanoparticles containing diazepam: preparation, optimization, characterization, in-vitro drug release and release kinetic study. *Nano Convergence.* 2016;3(1): 3–9. <https://doi.org/10.1186/s40580-016-0061-2>
8. Spain E. et al. High Sensitivity DNA Detection Based on Regioselectively Decorated Electrocatalytic Nanoparticles. *Anal. Chem.*2012; 84: 6471–6476, doi:10.1021/ac300458x
9. Fu T, Kong Q, Sheng H, Gao L. Value of Functionalized Superparamagnetic Iron Oxide Nanoparticles in the Diagnosis and Treatment of Acute Temporal Lobe Epilepsy on MRI. *Neural Plast.* 2016;2016:2412958. doi:10.1155/2016/2412958
10. Lopalco A. Oxcarbazepine-loaded polymeric nanoparticles : development and permeability studies across in vitro models of the blood – brain barrier and human placental trophoblast. *Int J Nanomedicine.* 2015;10:1985-1996. doi:10.2147/IJN.S77498
11. Sharma D, Sharma R.K, Sharma N, Gabrani R, Sharma S.K, Ali J Dang S. Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles. *AAPS PharmSciTech.* 2015; 16: 1108–1121.
12. Leila J, Mahnaz K, Najafzadeh H. Evaluation of Anticonvulsive Effect of Magnesium Oxide Nanoparticles in Comparison with Conventional MgO in Diabetic and Non-diabetic Male Mice. *Basic and Clinical neuro science.*2014 ;5(2): 156-161
13. Nair R, Kumar A. C. K, Priya V. K, Yadav C. M, & Raju P. Y. Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. *Lipids in Health and Disease.* 2012; 11(71):1-8. <https://doi.org/10.1186/1476-511X-11-72>

14. Leung K. DY-675-g7-Poly(lactic-co-glycolic acid) nanoparticles. 2010 Dec 1 [Updated 2011 Mar 3]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
15. Valentina Cena, & Pablo J. Nanoparticle crossing of blood – brain barrier : a road to new therapeutic approaches to central nervous system diseases, *Nanomedicine*.2018; 13 (13): 1513–1516.